ArticleJournal of natural medicines2025
Insight of action mechanism of Astragaloside IV for relieving of cerebral ischemic injury in a rat model of middle cerebral artery occlusion reperfusion via proteomics and network pharmacology.
Article in Journal of natural medicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular Mechanisms and Clinical Applications of Buyang Huanwu Decoction in the Treatment of Ischemic Stroke: A Review.International journal of general medicine · 2026Review
- Astragaloside IV suppresses neuroinflammation via PI3K/Akt/NF-κB to ameliorate cerebral ischemia-reperfusion injury based on network pharmacology analysis and experimental validation.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astragaloside IV (AS-IV) is the principal active component of Astragalus membranaceus (fisch.) Bge. var. mongholicus (Bge.) Hsiao. This study aims to explore action mechanism of AS-IV for relieving of cerebral ischemic injury in a rat model of middle cerebral artery occlusion reperfusion (MCAO) via proteomics and network pharmacology. Pharmacodynamics experiments showed that AS-IV could effectively alleviate MACO-induced cerebral infarction, preserve the structural integrity of neurons, and promote the formation of Sol bodies. In addition, TMT quantitative proteomics revealed differential proteins (DEPs), e.g., DGKQ, PPT1, Gnai3, Gnal, PLA2G4A, and Ppp2ca. These DEPs might be closely related to AS-IV for the therapeutic effects on ischemic stroke. In combination with network pharmacology, the PLA2G4A was further identified as key target protein of AS-IV ascribed to its involvement in the regulation of inflammatory mediators in the TRP pathway. Ultimately, in vitro validation demonstrated that AS-IV offers neuroprotective effects by targeting the PLA2G4A, reducing the release of arachidonic acid (AA) and COX-2, and facilitating Ca
Indexed as
Identifiers
40208491What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.